The MAGNETOM Viato.Mobile may facilitate improved access to MRI capabilities for patients with serious health conditions who lack geographic proximity to centers with advanced imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the MAGNETOM Viato.Mobile, a 1.5 Tesla magnetic resonance imaging (MRI) system that is reportedly designed for easy transportation to off-site locations.
The 70 centimeter-bore scanner offers a variety of features including BioMatrix Technology and Deep Resolve image reconstruction, according to Siemens Healthineers, the manufacturer of MAGNETOM Viato.Mobile.
The company said the artificial intelligence (AI)-powered Deep Resolve technology accelerates scan times for brain scans by up to 70 percent, enhances image resolution and improves signal-to-noise ratio. Siemens Healthineers added that BioMatrix Technology prevents variation in imaging results by enabling clinicians to personalize MRI exams and compensate for different patient anatomies and physiologies.
Jane Kilkenny, the vice president of magnetic resonance at Siemens Healthineers North America, said the MAGNETOM Viato.Mobile represents an opportunity to bring the capabilities of advanced imaging to patients who don’t have geographic proximity to facilities with these imaging systems.
“The MAGNETOM Viato.Mobile demonstrates our dedication to the mobile MR market by offering the latest and greatest technologies to patients who might lack convenient access to premium diagnostic MR scanners,” noted Kilkenny. “The introduction of the MAGNETOM Viato.Mobile is yet another example of our efforts to democratize high-end imaging technology to provide greater access to care.”
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.